← All indications
Breast Neoplasms
Tumors or cancer of the human BREAST.
Subtype terms (8)
More specific conditions that are subtypes of Breast Neoplasms in the MeSH hierarchy.
- Breast Carcinoma In Situ
12 drugs (11 approved, 1 experimental)
- Breast Neoplasms, Male
102 drugs (61 approved, 41 experimental)
- Carcinoma, Ductal, Breast
13 drugs (8 approved, 5 experimental)
- Carcinoma, Lobular
6 drugs approved
- Hereditary Breast and Ovarian Cancer Syndrome
10 drugs (6 approved, 4 experimental)
- Inflammatory Breast Neoplasms
45 drugs (36 approved, 9 experimental)
- Triple Negative Breast Neoplasms
425 drugs (120 approved, 305 experimental)
- Unilateral Breast Neoplasms
Drugs by status
Approved for this indication (62)
- palbociclib
- pertuzumab
- pamidronate
- anastrozole
- flucytosine
- sacituzumab govitecan
- atezolizumab
- inavolisib
- alpelisib
- technetium tc-99m sulfur colloid kit
- fluoroestradiol
- thiotepa
- methyltestosterone
- docetaxel
- gemcitabine
- neratinib maleate
- dexrazoxane
- elacestrant
- 4-hydroxycyclophosphamide
- testolactone
- fam-trastuzumab deruxtecan-nxki
- motexafin gadolinium
- Zanidatamab
- methotrexate
- fluorouracil
- dalpiciclib
- tucatinib
- rc48-adc
- toremifene
- tamoxifen
- +32 more
Phase 4 trials (108)
- hyaluronic acid
- sevoflurane
- s-1
- lenvatinib
- imatinib
- huaier
- iodine
- prasterone
- oxycodone
- centella asiatica
- pyrotinib
- technetium tc 99m nanocolloid
- sacubitril
- ketorolac
- desflurane
- vancomycin
- boswellia serrata
- albumin nanocolloid
- levobupivacaine
- gadopenteate dimeglumine
- aprepitant
- dehydroepiandrosterone
- olaparib
- rimabotulinumtoxinB
- ramosetron
- desvenlafaxine
- toripalimab
- acetaminophen
- fluorocholine
- sargramostim
- +78 more
Phase 3 trials (265)
- lactic acid
- capsaicin
- busulfan
- lasofoxifene
- ibuprofen
- tqb2102
- calcium carbonate
- tesmilifene
- prochlorperazine
- progestin
- vepdegestrant
- essential oils
- melphalan
- vitamin d3
- pentoxifylline
- ganglioside
- hrs-8080
- magnesium sulfate
- clindamycin
- cycloserine
- oxygen
- bisoprolol
- kn026
- temsirolimus
- norethindrone
- eplerenone
- iparomlimab
- pf-07220060
- d-0502
- retifanlimab
- +235 more
Phase 2 trials (845)
- reolysin
- zongertinib
- avzo-021
- ravuconazole
- nicotine
- alvocidib
- alvac-cea vaccine
- 18 F-Fluoro-5α-Dihydrotestosterone
- multi-valent pneumococcal conjugate vaccine
- hydromorphone
- rintatolimod
- her-2 car-t cells
- azd-5672
- [177lu]lu-dpi-4452
- polysaccharide-k
- nimotuzumab
- tub-030
- nc762
- nogapendekin alfa inbakicept
- inactivated influenza vaccine
- lae005
- etbx-061
- y90 monoclonal antibody mn-14
- as15
- sgn-15
- sulfasalazine
- ficus septica leaf extract
- selicrelumab
- bebt-209
- 2x-121
- +815 more
Phase 1 trials (593)
- azd8835
- ucmym802
- ly-3023414
- 99mtc-abh2
- dm5167
- picoplatin
- cd133 car-t cells
- 95-5-49
- azd-8186
- mgc026
- aby-025
- egf816
- aprotinin
- iopamidol
- vmd-928
- iso-1
- 89zr-lncab104
- iks014
- mgd013
- fowlpox-sargramostim
- py314
- dm001
- canakinumab
- dzd1516
- cea gene modified t cells
- ocpm immunotherapeutic vaccine
- prgn-3007
- incomplete freund's adjuvant
- mm-111
- fluvoxamine
- +563 more
Other trials (144)
- lactobacillus casei
- primrose oil
- calendula
- chamomile
- 68ga-nota-nfb
- esmolol
- [68ga]ga-dota-h2d3
- zinc
- rhenium sulfur
- neutrophil
- tetracycline
- promestriene
- inotuzumab ozogamicin
- sertraline
- etidronate
- muc-1 peptide vaccine
- deciten
- beetroot juice
- 131 iodine
- Mentha x piperita
- sitosterols
- tp3805
- phytomed
- htert/survivin/cmv multipeptide vaccine
- fpprgd2
- hydroxytyrosol
- Zingiber officinale
- 68ga-nota-nectin-4 antibody fragment
- qishen
- lignans
- +114 more
Organizations
Organization Involved with Phase 4 Indications (118)
- Ghent University
- Assiut University
- University of British Columbia
- Shengjing Hospital
- American Cancer Society, Inc.
- Kettering Health Network
- iOMEDICO AG
- University of Zagreb
- German Breast Group Forschungs GmbH
- Tsinghua University
- Shandong University
- Shijiazhuang Pharma Group (CSPC)
- Institut Gustave Roussy
- Takeda
- Monash University
- Hospital Universitario Arnau de Vilanova de Lleida
- Catholic University of Sacred Heart, Rome
- Florida Department of Health
- Cephalon
- Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
- Charing Cross Hospital
- Korean Breast Cancer Society
- Anglo Celtic Cooperative Oncology Group
- University of Milan
- Isfahan University
- Horus University
- Radboud University
- Merck
- Sungkyunkwan University
- University of Lille
- +88 more
Organization Involved with Phase 3 Indications (476)
- Hellenic Oncology Research Group
- Johns Hopkins University
- Boehringer Ingelheim
- Institut de Cancérologie Lucien Neuwirth
- CHU Besançon
- Hospital General de Guadalajara
- Spectrum Pharmaceuticals
- University of Seville
- University of Modena and Reggio Emilia
- Borstkanker Onderzoek Groep
- Dutch Cancer Society
- Janssen Pharmaceutica NV
- Amgen
- University of Helsinki
- Elkhart General Hospital
- Loyola University
- Utrecht University
- Government of France
- Institut de Cancerologie de l'Ouest Paul Papin
- Hamamatsu Oncology Center
- Guizhou Medical University
- Universidad Autonoma de Barcelona
- University of Sheffield
- Hacettepe University
- Nationale Centrum für Tumorerkrankungen
- Alliance Foundation Trials
- Institut de Cancérologie de la Loire (ICLN)
- University of Crete
- Frontier Science and Technology Research Foundation Inc (FS)
- Astellas
- +446 more
Organization Involved with Phase 2 Indications (582)
- MDS Pharma
- Infinity Pharmaceuticals, Inc.
- All India Institute of Medical Sciences
- Big Ten Cancer Research Consortium
- Endocyte
- Centro Nacional de Investigaciones Oncológicas
- Smerud Medical Research Denmark
- McKesson
- Wiseman Research Initiatives, LLC
- HIS - Site Etterbeek - Ixelles - Belgium
- Activa Therapeutics
- Enzon
- Moorgreen Hospital, Southampton
- University of Arkansas
- Zymeworks Inc.
- Shenzhen Hank Bioengineering Institute
- Lignan Research Inc.
- SRI International
- University of Montreal
- Baylor University
- Veeda Clinical Research
- University of Grenoble
- Immunovative Therapies
- Azienda USL 4 Prato
- Effector Therapeutics
- Antisoma Research
- Hopital Morges
- Hospital General Universitario Gregorio Marañon
- Premiere Oncology
- Ozmosis Research Inc.
- +552 more
Organization Involved with Phase 1 Indications (153)
- Samus Therapeutics
- The START Center for Cancer Care
- Eastchester Center for Cancer Care
- Fortune Rock
- Xencor
- QED Therapeutics, Inc.
- University of Leicester
- Tokyo Medical University
- Northwell Health
- Creighton University
- Institut Pasteur
- AmpliMed Corporation
- InventisBio Inc.
- BioGene Life Science
- Bavarian Nordic
- Suzhou Kintor Pharmaceutical Inc,
- Qassim University
- Mary Crowley Cancer Center
- MannKind Corp
- IRX Therapeutics
- Van Andel Research Institute
- Avera Cancer Institute
- Center Trials & Treatment Inc.
- Seragon Pharmaceuticals
- HUYA Bioscience International
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Zeno Pharmaceuticals
- Pinnacle Research Group
- Al Azhar University
- Overlake Medical Center
- +123 more
Organization Involved with Other Experimental Indications (73)
- Scariot Foundation
- Universidad Europea de Madrid
- Avanti Tutta Onlus
- Big C Local Cancer Research and Care
- Nalagenetics Pte Ltd
- Mitaka USA, Inc.
- Park Nicollet
- University of Natural Resources and Life Sciences
- Government of Poland
- Bangladesh Medical University
- CHU Jean Verdier
- Cancer Registry of Norway
- Hospital Provincial Magdalena V. de Martínez
- University of East Anglia
- Regulatory and Clinical Research Institute Inc
- University of Belgrade
- Beijing Digital Precision Medicine Company
- François Rabelais University
- University of Reims
- Yijishan Hospital of Wannan Medical College
- South West Sydney Local Health District
- I-Flow
- Government of Spain
- The Hong Kong Polytechnic University
- Umea University
- Federal University of Sao Paulo
- American Holistic Nurses Association
- Cancer Research Malaysia
- American Nurses Foundation
- Read-Gene S.A.
- +43 more